{"id":53447,"date":"2023-01-31T11:02:03","date_gmt":"2023-01-31T10:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pharmaceuticals-and-biopharmaceuticals-lab-instrumentation-markets-report-2022-in-depth-examination-of-the-major-technologies-used-in-the-pharma-bio-sector-comprising-50-technologies-in-9-categories\/"},"modified":"2023-01-31T11:02:03","modified_gmt":"2023-01-31T10:02:03","slug":"pharmaceuticals-and-biopharmaceuticals-lab-instrumentation-markets-report-2022-in-depth-examination-of-the-major-technologies-used-in-the-pharma-bio-sector-comprising-50-technologies-in-9-categories","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pharmaceuticals-and-biopharmaceuticals-lab-instrumentation-markets-report-2022-in-depth-examination-of-the-major-technologies-used-in-the-pharma-bio-sector-comprising-50-technologies-in-9-categories\/","title":{"rendered":"Pharmaceuticals and Biopharmaceuticals Lab Instrumentation Markets Report 2022: In-depth Examination of the Major Technologies Used in the Pharma\/Bio Sector, Comprising 50 Technologies in 9 Categories – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Lab Instrumentation Markets for Pharmaceuticals and Biopharmaceuticals”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nLab Instrumentation Markets for Pharmaceuticals and Biopharmaceuticals <\/em>is an in-depth examination of the major technologies used in the pharma\/bio sector, encompassing 50 technologies in 9 categories.\n<\/p>\n

\nThe report examines historical growth and provides forecasts for demand over the next five years. This report focuses on delivering insights into phases of discovery, therapeutic focus, and the challenges being faced in therapeutic development.\n<\/p>\n

\nDrug development is a long and complicated process that involves several types of analytical instruments used in a variety of ways and purposes. Starting at early discovery, a targeted process occurs during drug and biomarker discovery to identify a drug candidate.\n<\/p>\n

\nThese drug candidates are then tested in preclinical and clinical trials, translational research, and finally manufacturing and QA\/QC. Due to the nature of drugs and their interactions, knowing how a drug works, its side effects, the method of delivery, its efficacy, consistency in manufacturing, and more all must be tested using precise methods and accurate data.\n<\/p>\n

\nThe instruments covered in this report are the primary sources of that data and form the critical infrastructure for pharmaceutical and biotherapeutic compounds. Further, innovations in the instruments, software controlling them, and analysis methods will further drive new biotherapeutics and drug formulations that are key to the success of the industry.\n<\/p>\n

\nAt the heart of all drug development is the pharmaceutical, biotech, and biopharmaceutical companies. They account for the majority of demand for these instruments, as they are the main commercial benefactors of biotherapeutics.\n<\/p>\n

\nThese companies will often utilize contract research organizations and public sector organizations such as those in academia, the government, and research institutions to assist in the R&D process. Together and in conjunction with a regulatory framework, this network alongside instrument suppliers forms a fast growing marketplace that has only been further helped by steady government investment.\n<\/p>\n

\nFuture growth in the pharma\/bio marketplace will be driven by new therapeutic modalities that are more specific to a certain disease, delivered in better ways, with faster research and production timelines, and an increased reliance on personalization to patients. The resulting price tag and need for specific capital and infrastructure will further rely on high throughput screening, automation, and reliance on CROs and CMOs that provide expertise and scale up resources.\n<\/p>\n

\nTop Vendors include:<\/strong>\n<\/p>\n